Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.97
+4.82 (2.40%)
AAPL  265.66
+1.78 (0.68%)
AMD  202.26
-0.82 (-0.40%)
BAC  53.24
+0.50 (0.96%)
GOOG  304.73
+1.91 (0.63%)
META  639.99
+0.70 (0.11%)
MSFT  401.59
+4.73 (1.19%)
NVDA  189.13
+4.16 (2.25%)
ORCL  156.99
+3.02 (1.96%)
TSLA  415.45
+4.82 (1.18%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.